Ilsung Is Past Earnings Performance
Past criteria checks 0/6
Ilsung Is has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 12.2% per year.
Key information
16.9%
Earnings growth rate
14.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 12.2% |
| Return on equity | -5.4% |
| Net Margin | -27.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Reflecting on Ilsung Pharmaceuticals' (KRX:003120) Share Price Returns Over The Last Three Years
Feb 20
Ilsung Pharmaceuticals (KRX:003120) Is Growing Earnings But Are They A Good Guide?
Jan 16Here's What Ilsung Pharmaceuticals Co., Ltd.'s (KRX:003120) Shareholder Ownership Structure Looks Like
Dec 18
Reflecting on Ilsung Pharmaceuticals' (KRX:003120) Share Price Returns Over The Last Three Years
Nov 21Revenue & Expenses Breakdown
How Ilsung Is makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 73,225 | -20,182 | 34,770 | 298 |
| 31 Mar 24 | 76,110 | -16,528 | 39,176 | 301 |
| 31 Dec 23 | 78,053 | -20,941 | 41,055 | 588 |
| 30 Sep 23 | 73,179 | 7,585 | 36,816 | 1,004 |
| 30 Jun 23 | 71,094 | 6,387 | 35,860 | 615 |
| 31 Mar 23 | 64,110 | 103,059 | 28,678 | 1,720 |
| 31 Dec 22 | 61,248 | 108,669 | 23,188 | 1,512 |
| 30 Sep 22 | 56,672 | 107,092 | 21,958 | 1,424 |
| 30 Jun 22 | 51,288 | 104,560 | 19,880 | 1,377 |
| 31 Mar 22 | 48,368 | 4,809 | 18,382 | 246 |
| 31 Dec 21 | 42,090 | -1,368 | 16,418 | 99 |
| 30 Sep 21 | 39,735 | -2,747 | 15,062 | 76 |
| 30 Jun 21 | 38,899 | -2,851 | 14,036 | 86 |
| 31 Mar 21 | 38,226 | -2,977 | 13,302 | 57 |
| 31 Dec 20 | 40,601 | 3,220 | 13,728 | 109 |
| 30 Sep 20 | 43,328 | 4,465 | 14,933 | 112 |
| 30 Jun 20 | 44,768 | 3,491 | 16,066 | 118 |
| 31 Mar 20 | 47,658 | 6,900 | 17,213 | 138 |
| 31 Dec 19 | 48,412 | 6,719 | 18,003 | 93 |
| 30 Sep 19 | 51,760 | 3,982 | 18,236 | 135 |
| 30 Jun 19 | 52,551 | 4,198 | 18,404 | 130 |
| 31 Mar 19 | 55,969 | 1,509 | 18,688 | 473 |
| 31 Dec 18 | 61,653 | 2,946 | 18,965 | 132 |
| 30 Sep 18 | 61,220 | 2,386 | 19,615 | 108 |
| 30 Jun 18 | 65,724 | 2,936 | 20,306 | 327 |
| 31 Mar 18 | 67,416 | 2,497 | 22,142 | -63 |
| 31 Dec 17 | 67,043 | 2,629 | 22,185 | 304 |
| 30 Sep 17 | 68,424 | 3,709 | 22,137 | 322 |
| 30 Jun 17 | 69,260 | 3,292 | 22,850 | 167 |
| 31 Mar 17 | 68,070 | 3,848 | 21,348 | 209 |
| 31 Dec 16 | 67,463 | 3,017 | 21,169 | 237 |
| 30 Sep 16 | 66,040 | 96,725 | 20,610 | 270 |
| 30 Jun 16 | 63,561 | 97,016 | 19,139 | 250 |
| 31 Mar 16 | 62,766 | 97,235 | 18,490 | 285 |
| 31 Dec 15 | 61,745 | 98,854 | 18,192 | 319 |
| 30 Sep 15 | 61,790 | 5,071 | 17,747 | 331 |
| 30 Jun 15 | 62,180 | 5,842 | 17,295 | 316 |
| 31 Mar 15 | 61,529 | 5,356 | 17,432 | 266 |
| 31 Dec 14 | 62,829 | 4,035 | 17,559 | 213 |
| 30 Sep 14 | 61,018 | 2,449 | 17,789 | 266 |
| 30 Jun 14 | 60,941 | 1,716 | 17,978 | 326 |
| 31 Mar 14 | 61,280 | 2,905 | 17,754 | 376 |
| 31 Dec 13 | 62,807 | 7,955 | 18,003 | 418 |
Quality Earnings: A003120 is currently unprofitable.
Growing Profit Margin: A003120 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A003120 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare A003120's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A003120 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.6%).
Return on Equity
High ROE: A003120 has a negative Return on Equity (-5.43%), as it is currently unprofitable.